Fortress Biotech, Inc. Price & Performance (FBIOP)

Fortress Biotech is set for a pivotal year after securing two FDA approvals—Emrosi for rosacea and UNLOXCYT for advanced skin cancer. The pending sale of subsidiary Checkpoint Therapeutics to Sun Pharma is expected to yield $28 million plus royalties, while the CUTX-101 drug application for Menkes disease awaits a September FDA decision.123

Fortress Biotech reported a 2024 net loss of $55.9 million and revenue of $57.7 million, both down from the previous year. Despite these declines, the company achieved notable milestones with two FDA approvals and a strategic acquisition, potentially offsetting recent financial challenges and laying groundwork for future growth.245

Analysts maintain a cautious outlook on Fortress Biotech, citing high short interest and a negative P/E ratio. Technical indicators are mixed, with some buy signals in short-term averages but broader metrics suggesting the stock is overvalued. Recent price declines and financial losses highlight the risks facing shareholders.675